Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with...
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension
About this item
Full title
Author / Creator
Publisher
Cambridge, UK: Cambridge University Press
Journal title
Language
English
Formats
Publication information
Publisher
Cambridge, UK: Cambridge University Press
Subjects
More information
Scope and Contents
Contents
Macitentan is an orally active, potent, dual endothelin receptor antagonist and is the only registered treatment for pulmonary arterial hypertension that significantly reduced morbidity and mortality in a long-term event-driven study. Aim Few studies compared the clinical efficacy and safety of switch from bosentan to macitentan only in adult patie...
Alternative Titles
Full title
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2011280125
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2011280125
Other Identifiers
ISSN
1047-9511
E-ISSN
1467-1107
DOI
10.1017/S1047951117002542
